4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms

S. Marchini, G. Damia, M. Broggini, G. Pennella, M. Ripamonti, A. Marsiglio, C. Geroni

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The activity of 4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548), a new alkycycline with high antitumor activity against a broad range of cancer cells, was evaluated in vitro and in vivo in cells selected for resistance to different anticancer agents. Both in vitro and in vivo, PNU-159548 did retain its activity in cells expressing the multidrug resistance (MDR) phenotype, associated to MDR-1 gene overexpression or with an alteration in the topoisomerase II gene (altered MDR), independently on the drug used for the selection of the resistant cell line. According to these data, the intracellular uptake of PNU-159548 is not influenced by the presence of MDR-1. PNU-159548 was also active, both in vitro and in vivo, against cells showing resistance to various alkylating agents (including cisplatin, cyclophosphamide, and melphalan) and topoisomerase I-inhibitors. Cells defective in nucleotide excision repair, which did show hypersensitivity to treatment with UV irradiation and alkylating agents, showed only a marginally increased sensitivity to PNU-159548. Similarly, the activity of the drug was not influenced by the mismatch repair system, as assessed in two different cellular systems deficient in hMLH1 expression and in which hMLHI activity was restored by chromosome 3 transfer. The results obtained clearly indicate that the new anticancer agent PNU-159548 is able to overcome the classical mechanisms of resistance emerging after treatment with the most clinically used anticancer agents, and it could represent an alternate choice in the treatment of those tumors refractory to conventional therapy.

Original languageEnglish
Pages (from-to)1991-1995
Number of pages5
JournalCancer Research
Volume61
Issue number5
Publication statusPublished - Mar 1 2001

Fingerprint

Daunorubicin
Tumor Cell Line
Antineoplastic Agents
MDR Genes
Alkylating Agents
Multiple Drug Resistance
Topoisomerase I Inhibitors
Type II DNA Topoisomerase
DNA Mismatch Repair
Chromosomes, Human, Pair 3
Melphalan
DNA Repair
Pharmaceutical Preparations
Cyclophosphamide
Cisplatin
4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulfonyldaunorubicin
Neoplasms
Hypersensitivity
Phenotype
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. / Marchini, S.; Damia, G.; Broggini, M.; Pennella, G.; Ripamonti, M.; Marsiglio, A.; Geroni, C.

In: Cancer Research, Vol. 61, No. 5, 01.03.2001, p. 1991-1995.

Research output: Contribution to journalArticle

@article{45186c0cd37d44d38ee189643dea04ff,
title = "4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms",
abstract = "The activity of 4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548), a new alkycycline with high antitumor activity against a broad range of cancer cells, was evaluated in vitro and in vivo in cells selected for resistance to different anticancer agents. Both in vitro and in vivo, PNU-159548 did retain its activity in cells expressing the multidrug resistance (MDR) phenotype, associated to MDR-1 gene overexpression or with an alteration in the topoisomerase II gene (altered MDR), independently on the drug used for the selection of the resistant cell line. According to these data, the intracellular uptake of PNU-159548 is not influenced by the presence of MDR-1. PNU-159548 was also active, both in vitro and in vivo, against cells showing resistance to various alkylating agents (including cisplatin, cyclophosphamide, and melphalan) and topoisomerase I-inhibitors. Cells defective in nucleotide excision repair, which did show hypersensitivity to treatment with UV irradiation and alkylating agents, showed only a marginally increased sensitivity to PNU-159548. Similarly, the activity of the drug was not influenced by the mismatch repair system, as assessed in two different cellular systems deficient in hMLH1 expression and in which hMLHI activity was restored by chromosome 3 transfer. The results obtained clearly indicate that the new anticancer agent PNU-159548 is able to overcome the classical mechanisms of resistance emerging after treatment with the most clinically used anticancer agents, and it could represent an alternate choice in the treatment of those tumors refractory to conventional therapy.",
author = "S. Marchini and G. Damia and M. Broggini and G. Pennella and M. Ripamonti and A. Marsiglio and C. Geroni",
year = "2001",
month = "3",
day = "1",
language = "English",
volume = "61",
pages = "1991--1995",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - 4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms

AU - Marchini, S.

AU - Damia, G.

AU - Broggini, M.

AU - Pennella, G.

AU - Ripamonti, M.

AU - Marsiglio, A.

AU - Geroni, C.

PY - 2001/3/1

Y1 - 2001/3/1

N2 - The activity of 4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548), a new alkycycline with high antitumor activity against a broad range of cancer cells, was evaluated in vitro and in vivo in cells selected for resistance to different anticancer agents. Both in vitro and in vivo, PNU-159548 did retain its activity in cells expressing the multidrug resistance (MDR) phenotype, associated to MDR-1 gene overexpression or with an alteration in the topoisomerase II gene (altered MDR), independently on the drug used for the selection of the resistant cell line. According to these data, the intracellular uptake of PNU-159548 is not influenced by the presence of MDR-1. PNU-159548 was also active, both in vitro and in vivo, against cells showing resistance to various alkylating agents (including cisplatin, cyclophosphamide, and melphalan) and topoisomerase I-inhibitors. Cells defective in nucleotide excision repair, which did show hypersensitivity to treatment with UV irradiation and alkylating agents, showed only a marginally increased sensitivity to PNU-159548. Similarly, the activity of the drug was not influenced by the mismatch repair system, as assessed in two different cellular systems deficient in hMLH1 expression and in which hMLHI activity was restored by chromosome 3 transfer. The results obtained clearly indicate that the new anticancer agent PNU-159548 is able to overcome the classical mechanisms of resistance emerging after treatment with the most clinically used anticancer agents, and it could represent an alternate choice in the treatment of those tumors refractory to conventional therapy.

AB - The activity of 4-demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl- daunorubicin (PNU-159548), a new alkycycline with high antitumor activity against a broad range of cancer cells, was evaluated in vitro and in vivo in cells selected for resistance to different anticancer agents. Both in vitro and in vivo, PNU-159548 did retain its activity in cells expressing the multidrug resistance (MDR) phenotype, associated to MDR-1 gene overexpression or with an alteration in the topoisomerase II gene (altered MDR), independently on the drug used for the selection of the resistant cell line. According to these data, the intracellular uptake of PNU-159548 is not influenced by the presence of MDR-1. PNU-159548 was also active, both in vitro and in vivo, against cells showing resistance to various alkylating agents (including cisplatin, cyclophosphamide, and melphalan) and topoisomerase I-inhibitors. Cells defective in nucleotide excision repair, which did show hypersensitivity to treatment with UV irradiation and alkylating agents, showed only a marginally increased sensitivity to PNU-159548. Similarly, the activity of the drug was not influenced by the mismatch repair system, as assessed in two different cellular systems deficient in hMLH1 expression and in which hMLHI activity was restored by chromosome 3 transfer. The results obtained clearly indicate that the new anticancer agent PNU-159548 is able to overcome the classical mechanisms of resistance emerging after treatment with the most clinically used anticancer agents, and it could represent an alternate choice in the treatment of those tumors refractory to conventional therapy.

UR - http://www.scopus.com/inward/record.url?scp=0035266297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035266297&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 1991

EP - 1995

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 5

ER -